MSTN and sarcopenia: As blocking myostatin using antibodies has been shown to beneficially affect muscle mass and grip strength in mice (Whittemore et al. 2003) and lean body mass and some functional parameters in old weak persons (Becker et al. 2015) it is not surprising that myostatin is consistently included in any suggested set of biomarkers for sarcopenia (Kalinkovich and Livshits 2015).